Table 1 Baseline demographics and clinical parameters
Variable | Category | |
|---|---|---|
Age, mean (years) | 42.8 ± 14.2 | |
Sex, n (%) | Female | 64 (62.7) |
Male | 38 (37.3) | |
Disease type, n (%) | Pancolitis | 49 (48.0) |
Left-sided colitis | 37 (36.3) | |
Proctitis | 16 (15.7) | |
(Distal type) | 40 (39.2) | |
Mayo endoscopic subscore, n (%) | Score 0 | 15 (14.7) |
Score 1 | 43 (42.2) | |
Score 2 | 29 (28.4) | |
Score 3 | 5 (4.9) | |
Simple clinical colitis activity index | Score 0 | 3 (2.9) |
(SCCAI), n (%) | Score 1–2 | 29 (28.4) |
Score ≥ 3 | 70 (68.6) | |
Simple clinical colitis activity index | 0 week | 4.0 ± 2.6 |
(SCCAI), mean | 2 weeks | 1.9 ± 2.0 |
6 weeks | 1.1 ± 1.7 | |
Bowel frequency (night) score, n (%) | 36 (35.3) | |
Defecation urgency score, n (%) | 45 (44.1) | |
Both bowel frequency (night) and | 27 (26.4) | |
defecation urgency score, n (%) | ||
Concomitant drug, n (%) | 5-ASA suppositories | 22 (21.5) |
5-ASA enemas | 3 (2.9) | |
Prednisolone suppositories | 1 (1.0) | |
Prednisolone enemas | 6 (5.8) | |
Immunomodulators, n (%) | 11 (10.7) | |
Biologics, n (%) | Infliximab | 5 (4.9) |
Golimumab | 3 (2.9) | |
Adalimumab | 2 (1.9) | |
Vedolizumab | 1 (1.0) | |
CRP at start of the observation, | 0.8 ± 1.6 | |
mean (mg/dl) |